MedTrace Logo

Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists

NCT02475057 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-06-12

No results posted yet for this study

Summary

The purpose of this study is to test whether Degarelix is associated with less endothelial dysfunction (an intermediate in the development of cardiac disease) and cardiovascular biomarkers compared to LHRH agonists.

Conditions

Interventions

DRUG

Degarelix (LHRH antagonist)

Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.

DRUG

LHRH agonist

LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.

DEVICE

EndoPAT2000

Peripheral arterial plethysmography using an EndoPAT2000 device

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    collaborator INDUSTRY

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • David Margel, MD, PhD · Rabin Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2018-07-31
Completion
2019-06-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02475057 on ClinicalTrials.gov